T-lymphoblastic lymphoma, also known as T-lymphoblastic lymphoma, has a high degree of malignancy and a low cure rate, and is expected to be cured with allogeneic hematopoietic stem cell transplantation, which often takes several months from the start of treatment to the end of hematopoietic stem cell transplantation.
T-lymphoblastoid lymphoma is extremely malignant, and clinically available chemotherapy regimens have limited efficacy in treating it, with some patients in an ineffective state from the start of treatment, and the disease tends to progress rapidly. Drugs include cyclophosphamide and vincristine.
Patients who are able to achieve remission after treatment are recommended to undergo allogeneic hematopoietic stem cell transplantation as soon as possible, because allogeneic hematopoietic stem cell transplantation is the fundamental method that is expected to cure the disease. However, although allogeneic hematopoietic stem cell transplantation is expected to be a cure, it is not 100 percent effective and there is a risk of the disease coming back after transplantation.
Overall, T-lymphoblastic lymphoma is poorly treated and has a short survival period, so it is recommended to actively cooperate with doctors to standardize treatment.